[go: up one dir, main page]

GB202216168D0 - Route of administration - Google Patents

Route of administration

Info

Publication number
GB202216168D0
GB202216168D0 GBGB2216168.1A GB202216168A GB202216168D0 GB 202216168 D0 GB202216168 D0 GB 202216168D0 GB 202216168 A GB202216168 A GB 202216168A GB 202216168 D0 GB202216168 D0 GB 202216168D0
Authority
GB
United Kingdom
Prior art keywords
administration
route
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2216168.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Priority to GBGB2216168.1A priority Critical patent/GB202216168D0/en
Publication of GB202216168D0 publication Critical patent/GB202216168D0/en
Priority to KR1020257017892A priority patent/KR20250097939A/en
Priority to AU2023374427A priority patent/AU2023374427A1/en
Priority to CN202380076375.3A priority patent/CN120129536A/en
Priority to IL320423A priority patent/IL320423A/en
Priority to PCT/EP2023/080220 priority patent/WO2024094612A1/en
Priority to TW112141560A priority patent/TW202432190A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB2216168.1A 2022-10-31 2022-10-31 Route of administration Ceased GB202216168D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB2216168.1A GB202216168D0 (en) 2022-10-31 2022-10-31 Route of administration
KR1020257017892A KR20250097939A (en) 2022-10-31 2023-10-30 Route of administration
AU2023374427A AU2023374427A1 (en) 2022-10-31 2023-10-30 Route of administration
CN202380076375.3A CN120129536A (en) 2022-10-31 2023-10-30 Route of administration
IL320423A IL320423A (en) 2022-10-31 2023-10-30 Route of administration
PCT/EP2023/080220 WO2024094612A1 (en) 2022-10-31 2023-10-30 Route of administration
TW112141560A TW202432190A (en) 2022-10-31 2023-10-30 Route of administration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2216168.1A GB202216168D0 (en) 2022-10-31 2022-10-31 Route of administration

Publications (1)

Publication Number Publication Date
GB202216168D0 true GB202216168D0 (en) 2022-12-14

Family

ID=84839429

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2216168.1A Ceased GB202216168D0 (en) 2022-10-31 2022-10-31 Route of administration

Country Status (7)

Country Link
KR (1) KR20250097939A (en)
CN (1) CN120129536A (en)
AU (1) AU2023374427A1 (en)
GB (1) GB202216168D0 (en)
IL (1) IL320423A (en)
TW (1) TW202432190A (en)
WO (1) WO2024094612A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
JP7436089B2 (en) 2016-03-02 2024-02-21 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア Treatment of frontotemporal dementia
KR102697811B1 (en) 2017-10-03 2024-08-22 프리베일 테라퓨틱스, 인크. Gene therapy for lysosomal disorders
US20230277687A1 (en) * 2020-08-06 2023-09-07 Fundacion Para La Investigacion Medica Aplicada Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy
CA3188748A1 (en) 2020-08-12 2022-02-17 UCB Biopharma SRL Gene therapy using nucleic acid constructs comprising methyl cpg binding protein 2 (mecp2) promoter sequences
TW202227633A (en) 2020-08-26 2022-07-16 賓州大學委員會 Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration

Also Published As

Publication number Publication date
IL320423A (en) 2025-06-01
TW202432190A (en) 2024-08-16
CN120129536A (en) 2025-06-10
KR20250097939A (en) 2025-06-30
WO2024094612A1 (en) 2024-05-10
AU2023374427A1 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
GB2595415B (en) Compensation of own voice occlusion
IL291674A (en) Interconnection of drug administration systems
IL309664A (en) Administration of anti-hpa-1a antibodies
IL291273A (en) Intranasal administration of esketamine
GB202411655D0 (en) Application of circHIF1a
IL283286A (en) Pharmaceutical formulations of cyclosporine analogs
SMT202400066T1 (en) Separation of microplastics
IL320423A (en) Route of administration
GB202216166D0 (en) Route of administration
GB202103774D0 (en) Detectiion of Ransomware
IL299308A (en) Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine
GB202215863D0 (en) Preparation of neosaxitoxin
GB2604751B (en) Construction of an Arch
CA213269S (en) Pair of earphones
GB2624634B (en) Integration of Projector
ZA202205263B (en) Solid pharmaceutical forms of perampanel
IL313482A (en) Stable formulations of shr0302
GB202106811D0 (en) Alignment of map segments
GB202314050D0 (en) Novel form of bemcentinib
GB202106943D0 (en) Construction of an arch
GB202215264D0 (en) Use of urolithins
GB202310293D0 (en) Amending flight route to avoid restricted area
GB202207008D0 (en) Line of draw
GB202311051D0 (en) Means of constructing octocopter
PH32023050720S1 (en) Pair of earphones

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)